Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

436.48 -3.58 (-0.81%)
Streaming Delayed Price Updated: 12:50 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 Next >
United Therapeutics to Feature Clinical Data at the CHEST 2025 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare Forum
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society Congress
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports First Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report First Quarter 2025 Financial Results Before Market Open on Wednesday, April 30, 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to Work
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the Pulmonary Vascular Research Institute 2025 Annual Congress
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Announces Successful World’s First UKidney Transplant
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Reports Third Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion Service
From United Therapeutics Corporation
Via Business Wire
United Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024
From United Therapeutics Corporation
Via Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual Meeting
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.